Sean Plunkett Email

VP, Manufacturing and Device Engineering . Aerovate Therapeutics

Current Roles

Employees:
50
Revenue:
$5.6M
About
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH).
Aerovate Therapeutics Address
Boston, MA 02116, US
Boston, MA
United States
Aerovate Therapeutics Email

Past Companies

Aerovate Therapeutics, Inc.Vice President, Manufacturing and Device Engineering
Acorda Therapeutics, Inc.Executive Director, Device and Program Management
Civitas TherapeuticsDirector

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.